featured
Ipilimumab With or Without Nivolumab for PD-1 or PD-L1 Blockade–Refractory Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Nat. Med. 2023 Aug 17;[EPub Ahead of Print], A VanderWalde, SL Bellasea, KL Kendra, NI Khushalani, KM Campbell, PO Scumpia, LF Kuklinski, F Collichio, JA Sosman, A Ikeguchi, AI Victor, TG Truong, B Chmielowski, DC Portnoy, Y Chen, K Margolin, C Bane, CA Dasanu, DB Johnson, Z Eroglu, S Chandra, E Medina, CR Gonzalez, I Baselga-Carretero, A Vega-Crespo, IP Garcilazo, E Sharon, S Hu-Lieskovan, SP Patel, KF Grossmann, J Moon, MC Wu, A RibasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.